Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
|
After market
04:23:27 pm
|
1.34
USD
|
-3.60%
|
|
1.335
|
-0.37%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
244.9
|
67.68
|
34.15
|
10
|
-
|
-
|
Enterprise Value (EV)
1 |
244.9
|
67.68
|
34.15
|
10
|
10
|
10
|
P/E ratio
|
-13.4
x
|
-3.58
x
|
-1.33
x
|
-0.24
x
|
-0.5
x
|
-0.53
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
188
x
|
55.4
x
|
48.2
x
|
62.5
x
|
37.5
x
|
-
|
EV / Revenue
|
188
x
|
55.4
x
|
48.2
x
|
62.5
x
|
37.5
x
|
-
|
EV / EBITDA
|
-14,804,685
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-1.77
x
|
-0.45
x
|
-0.63
x
|
-0.83
x
|
FCF Yield
|
-
|
-
|
-56.5%
|
-220%
|
-160%
|
-120%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,029
|
2,102
|
2,511
|
7,198
|
-
|
-
|
Reference price
2 |
120.7
|
32.20
|
13.60
|
1.390
|
1.390
|
1.390
|
Announcement Date
|
3/11/22
|
3/10/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5.63
|
1.306
|
1.222
|
0.709
|
0.16
|
0.2667
|
-
|
EBITDA
|
-
|
-16.54
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-17.46
|
-18.04
|
-21.03
|
-22.54
|
-24.54
|
-32.42
|
Operating Margin
|
-
|
-1,336.6%
|
-1,476.51%
|
-2,966.01%
|
-14,085.31%
|
-9,202.01%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-18.84
|
-21.41
|
-22.54
|
-28.03
|
-32.42
|
Net income
1 |
-3.721
|
-17.05
|
-18.84
|
-21.41
|
-22.54
|
-24.54
|
-32.42
|
Net margin
|
-66.09%
|
-1,305.21%
|
-1,541.33%
|
-3,020.17%
|
-14,085.31%
|
-9,202.01%
|
-
|
EPS
2 |
-
|
-9.000
|
-9.000
|
-10.20
|
-5.847
|
-2.807
|
-2.600
|
Free Cash Flow
1 |
-
|
-
|
-
|
-19.3
|
-22
|
-16
|
-12
|
FCF margin
|
-
|
-
|
-
|
-2,722.57%
|
-13,750%
|
-5,999.93%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/21
|
3/11/22
|
3/10/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.209
|
0.37
|
0.466
|
0.265
|
0.121
|
0.279
|
0.217
|
0.15
|
0.063
|
0.548
|
0.06
|
0.06
|
0.06
|
0.1
|
EBITDA
|
-3.8
|
-3.206
|
-3.297
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.032
|
-3.394
|
-4.221
|
-5.187
|
-5.239
|
-4.716
|
-5.712
|
-5.161
|
-5.44
|
-4.09
|
-5.242
|
-5.161
|
-5.32
|
-
|
Operating Margin
|
-1,929.19%
|
-917.3%
|
-905.79%
|
-1,957.36%
|
-4,329.75%
|
-1,690.32%
|
-2,632.26%
|
-3,440.67%
|
-8,634.92%
|
-746.35%
|
-8,737.5%
|
-8,601.67%
|
-8,865.83%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-5.624
|
-5.244
|
-4.456
|
-4.647
|
-5.632
|
-5.106
|
-6.028
|
-4.058
|
-5.49
|
-5.89
|
-6.59
|
-
|
Net income
1 |
-4.069
|
-3.51
|
-5.624
|
-5.244
|
-4.456
|
-4.647
|
-5.632
|
-5.904
|
-6.028
|
-4.058
|
-5.242
|
-5.161
|
-5.32
|
-
|
Net margin
|
-1,946.89%
|
-948.65%
|
-1,206.87%
|
-1,978.87%
|
-3,682.64%
|
-1,665.59%
|
-2,595.39%
|
-3,936%
|
-9,568.25%
|
-740.51%
|
-8,737.5%
|
-8,601.67%
|
-8,865.83%
|
-
|
EPS
2 |
-2.000
|
-1.700
|
-2.700
|
-2.500
|
-2.100
|
-2.200
|
-2.700
|
-2.800
|
-2.500
|
-1.610
|
-1.805
|
-1.655
|
-1.470
|
-0.7750
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/22
|
5/13/22
|
8/12/22
|
11/14/22
|
3/10/23
|
5/12/23
|
8/11/23
|
11/9/23
|
2/27/24
|
5/14/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-19.3
|
-22
|
-16
|
-12
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
0.3
|
0.2
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
42.45%
|
125%
|
-
|
-
|
Announcement Date
|
3/30/21
|
3/11/22
|
3/10/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
1.39
USD Average target price
14.05
USD Spread / Average Target +910.79% Consensus |
1st Jan change
|
Capi.
|
---|
| -90.15% | 10M | | +29.77% | 49.18B | | +1.00% | 42.11B | | +50.47% | 40.37B | | -5.26% | 28.85B | | +13.68% | 26.09B | | -22.99% | 18.71B | | +8.22% | 13.26B | | +32.41% | 12.32B | | -1.62% | 11.99B |
Other Biotechnology & Medical Research
|